SAB Biotherapeutics (SABS) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
SABS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SAB Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.87 |
| 52 Week High | US$5.01 |
| 52 Week Low | US$1.00 |
| Beta | 0.55 |
| 1 Month Change | 9.85% |
| 3 Month Change | 14.57% |
| 1 Year Change | -31.62% |
| 3 Year Change | -89.33% |
| 5 Year Change | n/a |
| Change since IPO | -98.16% |
Recent News & Updates
Recent updates
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
Sep 22
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02Shareholder Returns
| SABS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.1% | 1.8% | 1.4% |
| 1Y | -31.6% | -12.4% | 11.6% |
Return vs Industry: SABS underperformed the US Biotechs industry which returned -10.7% over the past year.
Return vs Market: SABS underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| SABS volatility | |
|---|---|
| SABS Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SABS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SABS's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 63 | Samuel Reich | www.sabbiotherapeutics.com |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc. Fundamentals Summary
| SABS fundamental statistics | |
|---|---|
| Market cap | US$17.28m |
| Earnings (TTM) | -US$34.28m |
| Revenue (TTM) | US$377.84k |
Is SABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SABS income statement (TTM) | |
|---|---|
| Revenue | US$377.84k |
| Cost of Revenue | US$29.76m |
| Gross Profit | -US$29.39m |
| Other Expenses | US$4.89m |
| Earnings | -US$34.28m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.69 |
| Gross Margin | -7,777.23% |
| Net Profit Margin | -9,071.77% |
| Debt/Equity Ratio | 0.6% |
How did SABS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 06:45 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SAB Biotherapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Keay Nakae | Chardan Capital Markets, LLC |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |